Clinical Trial Update: RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial from Mayo Clinic is evaluating whether RNA editing can serve as a biomarker to predict antidepressant response in adults with unipolar …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder

Snippet

Sponsor: Mayo Clinic | Conditions: Unipolar Depression, Bipolar Depression | Phase 4 | Status: RECRUITING